Derek Archila
Stock Analyst at Wells Fargo
(4.46)
# 324
Out of 5,113 analysts
224
Total ratings
57.24%
Success rate
17.74%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $1,264 → $1,317 | $833.16 | +58.07% | 15 | Jan 20, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $106 → $114 | $42.81 | +166.29% | 3 | Jan 20, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $129 → $145 | $103.39 | +40.25% | 7 | Jan 20, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $84 → $88 | $77.81 | +13.10% | 2 | Jan 20, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $322 → $330 | $233.65 | +41.24% | 16 | Jan 20, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $29 → $26 | $21.99 | +18.24% | 14 | Jan 20, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $479 → $376 | $361.35 | +4.05% | 2 | Jan 20, 2026 | |
| INCY Incyte | Downgrades: Equal-Weight | $116 → $107 | $102.58 | +4.31% | 12 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $22 → $30 | $22.39 | +33.99% | 9 | Jan 8, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Equal-Weight | $14 | $13.97 | +0.21% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $26.31 | +48.23% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $30 | $18.75 | +60.00% | 7 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $8.88 | +271.62% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $109 | $77.54 | +40.57% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $71.06 | +63.24% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $12.25 | +104.08% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $6.66 | +305.41% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 → $28 | $25.97 | +7.82% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $13.29 | +12.87% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $47.12 | +71.90% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $43.61 | -31.21% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.21 | -19.48% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.07 | +383.09% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.70 | +42.71% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $26.57 | +43.02% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $15.64 | +91.82% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.95 | -32.20% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.80 | +78.57% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $33.06 | -21.36% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $4.01 | +274.06% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $22.91 | -38.89% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $26.60 | +69.17% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.34 | +498.80% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.07 | +154.60% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $34.54 | +458.77% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $77.50 | -47.10% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.55 | +928.94% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $22.87 | +162.35% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $7.78 | +272.75% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.44 | +3,372.22% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $21.08 | +141.94% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $14.40 | +511.11% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $20.50 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $32.14 | - | 2 | Aug 3, 2017 |
argenx SE
Jan 20, 2026
Maintains: Overweight
Price Target: $1,264 → $1,317
Current: $833.16
Upside: +58.07%
Soleno Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $106 → $114
Current: $42.81
Upside: +166.29%
Rhythm Pharmaceuticals
Jan 20, 2026
Maintains: Overweight
Price Target: $129 → $145
Current: $103.39
Upside: +40.25%
BridgeBio Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $84 → $88
Current: $77.81
Upside: +13.10%
Ascendis Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $233.65
Upside: +41.24%
Apellis Pharmaceuticals
Jan 20, 2026
Maintains: Overweight
Price Target: $29 → $26
Current: $21.99
Upside: +18.24%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $361.35
Upside: +4.05%
Incyte
Jan 20, 2026
Downgrades: Equal-Weight
Price Target: $116 → $107
Current: $102.58
Upside: +4.31%
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $22.39
Upside: +33.99%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $14
Current: $13.97
Upside: +0.21%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $26.31
Upside: +48.23%
Dec 16, 2025
Maintains: Overweight
Price Target: $21 → $30
Current: $18.75
Upside: +60.00%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $8.88
Upside: +271.62%
Dec 16, 2025
Maintains: Overweight
Price Target: $91 → $109
Current: $77.54
Upside: +40.57%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $71.06
Upside: +63.24%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $12.25
Upside: +104.08%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $6.66
Upside: +305.41%
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $25.97
Upside: +7.82%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $13.29
Upside: +12.87%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $47.12
Upside: +71.90%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $43.61
Upside: -31.21%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.21
Upside: -19.48%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.07
Upside: +383.09%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.70
Upside: +42.71%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $26.57
Upside: +43.02%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $15.64
Upside: +91.82%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.95
Upside: -32.20%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.80
Upside: +78.57%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $33.06
Upside: -21.36%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $4.01
Upside: +274.06%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $22.91
Upside: -38.89%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $26.60
Upside: +69.17%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.34
Upside: +498.80%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $7.07
Upside: +154.60%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $34.54
Upside: +458.77%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $77.50
Upside: -47.10%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.55
Upside: +928.94%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $22.87
Upside: +162.35%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $7.78
Upside: +272.75%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.44
Upside: +3,372.22%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $21.08
Upside: +141.94%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $14.40
Upside: +511.11%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $20.50
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $32.14
Upside: -